Advisory
Committee for Pharmaceutical Science Meeting
Topic: Nomenclature
Prepared by: Moheb Nasr, Ph.D.
Date:
Nomenclature - Issues and Challenges
Pharmaceutical nomenclature must serve
the needs of the scientific, regulatory, public health, legal and marketing
communities. Developing nomenclature is a complicated process that engages many
governmental, private and public enterprises. The coordination of the efforts
by these many communities and organizations is not systematic. It is a real
challenge for companies engaged in finding new technologies for the delivery of
drugs to also find an acceptable nomenclature for their new product. From the
Agency perspective, we face several challenges in the development of science-based
legal terminology. The refinement of older terms of art used for centuries by
the pharmaceutical industry with newer standards-based definitions is a major
issue. Another is the replacement of older dosage forms by newer technologies
that have no precedents. Also, the Agency must be aware of bothersome advantage
an innovator may inadvertently gain by an overly restrictive definition that
allows a virtual monopoly on a particular dosage form. The Agency is also
responsible for items in the cosmetic and over-the counter industries, which
have different issues requiring another level of oversight. Furthermore, the
Agency is interested in harmonizing nomenclature practices to be used
throughout the world. Given these challenges, it is imperative that clear and
concise names be developed to promote accurate recognition and improve medical
communication for a safer health care system.
Committee Discussion
1. How can the Agency best implement new
nomenclature or change existing nomenclature to comply with newer standards?
2. Is it reasonable or useful
to include a quantifiable attribute when defining a dosage form or
distinguishing between closely related dosage forms where appropriate? Can such an approach be viewed as too
arbitrary in some cases and too rigid in other cases?
3. Has the update on topical
dosage forms presented today addressed the questions/comments raised by the
ACPS at the March 2003 meeting?
4. Is the proposed criterion,
i.e., USP disintegration time of less than one minute, reasonable for defining
an orally disintegrating tablet?